Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Young engineers are often more excited about solving technical problems than meeting immediate needs; consequently, they end up creating new devices or materials without knowing where and how they might be useful. But early in his career, materials scientist Darrell Irvine, PhD ‘00, decided that he didn’t want to find himself in that position. Instead, he immersed himself in immunology, a complex and exciting field where materials science hadn’t been applied much, and began building solutions to its particular problems. “It seemed it was an area where you could intervene with smart materials,” Irvine says.

Irvine began his work in immunology at Stanford University, where he spent almost two years as a postdoc. Walking in with minimal knowledge of immunology was “mostly frightening,” he says. But he didn’t let that deter him. He spent long hours in the lab, essentially taking a crash course in immu­nology, before coming back to MIT in 2002 to start his own lab as an assistant professor of biomedical engineering. One of his main projects now is designing and testing tiny particles of synthetic material as a way to package and deliver vaccines. He hopes that this new kind of packaging will help vaccines stimulate stronger and more effective immune responses, while avoiding some common side effects such as inflammation, fever, and shock.

Although other researchers have worked on combining biomaterials with vaccines, Mark Saltzman, SM ‘84, PhD ‘87, a chemical- and biomedical-engineering professor at Yale University, says Irvine is different. “People like Darrell have decided that they need to have a high level of sophistication in both areas of science to really make progress,” he says. Indeed, Irvine believes that his time at Stanford elevated the quality of his research. Instead of making technology that will work for something somewhere someday, he will try to apply his skills to particular problems in the hope that he can enhance the basic understanding of immunity.

Cell Commandos
On a computer monitor, Irvine plays a time-lapse, black-and-white video of mouse immune cells in a lab dish interacting with one of his synthetic materials. The video, at 40-times magnification, shows dozens of immune cells, called dendritic cells, swarming around a single microparticle. Like football players jumping on a fumbled ball, the cells pile on top of the microparticle until it almost disappears.

In the video, the microparticle is simulating the body’s response to an invading pathogen, such as a virus. When a virus enters the body, it stimulates the cells near the site of infection to release specific immune-signaling molecules. These molecules in turn call in the dendritic cells. Acting like a reconnaissance team, the dendritic cells arrive at the infection site and absorb samples of the virus. They then carry their samples to the lymph nodes, to instruct other immune cells to hunt down and destroy the rest of the virus population.

Viruses initiate strong immune responses, but new vaccines under development do not. This could be one reason why they have often been ineffective, providing little protection against future infection.

Irvine says vaccines that use biomaterials could succeed where their predecessors have failed. His microparticle, about 10 to 20 micrometers in diameter and made of a biodegradable polymer used in other medical devices, carries and slowly releases the immune-signaling molecules that attract dendritic cells. Vaccines under development haven’t been very good at rallying these cells. Irvine’s team has already shown that the microparticles work in lab dishes and is now working to prove that they will elicit the same response in mice.

But the migration of dendritic cells is only the first step in the immune response. The cells also need to collect samples of the virus and call in reinforcements. For this step, Irvine has created other, much smaller particles. These nanoparticles, roughly .5 micrometers to one micrometer in diameter, carry with them two different types of molecules: one instructs the dendritic cells to head for the lymph nodes, and another identifies the pathogen the immune system must seek.

Ultimately, Irvine believes, the two types of particles could work together in a vaccine. The microparticles would attract the dendritic cells, and the nanoparticles would give them their marching orders. Irvine and his team are now trying to bind the nanoparticles to the surface of the larger microparticle, so that they can work in concert.

0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me